Why the study?
Does warfarin prevent recurrent venous thromboembolism in patients with the factor V Leiden mutation, and does the nature of the first event predict recurrence?
Population
Patients with the factor V Leiden mutation following a first thrombotic event.
Comparison
Warfarin vs Stopping warfarin / off warfarin
Design
Cohort
Follow-up
9 years (median time to recurrence after stopping warfarin)
Authors
Loading...
May support finite anticoagulation after precipitated events in factor V Leiden; leaves open optimal duration pending prospective confirmation.
Does warfarin prevent recurrent venous thromboembolism in patients with the factor V Leiden mutation, and does the nature of the first event predict recurrence?
Long-term oral anticoagulation may not be justified in all patients with the factor V Leiden mutation following a first thrombotic event, as recurrence risk is significantly lower if the initial event was precipitated rather than idiopathic.
Baglin et al. (1998) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: